STUDY OBJECTIVES: To define which leg movements (LM) associated with restless legs syndrome (RLS) respond to dopamine-agonist treatment and verify if they fall within current diagnostic criteria for periodic LM during sleep (PLMS). DESIGN: Single-blind placebo-controlled study. SETTINGS: Sleep laboratory. PATIENTS: 43 consecutive untreated patients with idiopathic restless legs syndrome. INTERVENTIONS:Patients underwent clinical and neurophysiological evaluation, hematological screening, and 2 consecutive full-night polysomnographic studies. Before the second polysomnographic study, all patients were randomized to receive 0.25 mg of pramipexole or placebo. MEASUREMENTS AND RESULTS:LM parameters such as duration, amplitude, interval, and periodicity were analyzed. Compared to placebo, pramipexole significantly (P < 0.01) reduced PLMS while increasing sleep efficiency. Specifically we observed a significant (P < 0.01) reduction in LM ranging 2-4 s in duration and with intermovement interval of 6-46 s and a significant decrease in the periodicity of motor events. No effect of pramipexole was observed on isolated LM. CONCLUSIONS: These results support a heterogeneous basis for LM in RLS patients; while isolated LM do not respond to pramipexole treatment, most, but not all, PLMS classified by means of the current criteria do. Further studies with different pramipexole doses or dopamine agonists with different receptor-binding preference are warranted to better define the borders of dopamine response of PLMS.
RCT Entities:
STUDY OBJECTIVES: To define which leg movements (LM) associated with restless legs syndrome (RLS) respond to dopamine-agonist treatment and verify if they fall within current diagnostic criteria for periodic LM during sleep (PLMS). DESIGN: Single-blind placebo-controlled study. SETTINGS: Sleep laboratory. PATIENTS: 43 consecutive untreated patients with idiopathic restless legs syndrome. INTERVENTIONS:Patients underwent clinical and neurophysiological evaluation, hematological screening, and 2 consecutive full-night polysomnographic studies. Before the second polysomnographic study, all patients were randomized to receive 0.25 mg of pramipexole or placebo. MEASUREMENTS AND RESULTS: LM parameters such as duration, amplitude, interval, and periodicity were analyzed. Compared to placebo, pramipexole significantly (P < 0.01) reduced PLMS while increasing sleep efficiency. Specifically we observed a significant (P < 0.01) reduction in LM ranging 2-4 s in duration and with intermovement interval of 6-46 s and a significant decrease in the periodicity of motor events. No effect of pramipexole was observed on isolated LM. CONCLUSIONS: These results support a heterogeneous basis for LM in RLS patients; while isolated LM do not respond to pramipexole treatment, most, but not all, PLMS classified by means of the current criteria do. Further studies with different pramipexole doses or dopamine agonists with different receptor-binding preference are warranted to better define the borders of dopamine response of PLMS.
Authors: Martin Michaud; Marie Dumont; Brahim Selmaoui; Jean Paquet; Maria Livia Fantini; Jacques Montplaisir Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: Marco Zucconi; Raffaele Ferri; Richard Allen; Paul Christian Baier; Oliviero Bruni; Sudhansu Chokroverty; Luigi Ferini-Strambi; Stephany Fulda; Diego Garcia-Borreguero; Wayne A Hening; Max Hirshkowitz; Birgit Högl; Magdolna Hornyak; Martin King; Pasquale Montagna; Liborio Parrino; Giuseppe Plazzi; Mario G Terzano Journal: Sleep Med Date: 2006-02-03 Impact factor: 3.492
Authors: Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Julio Cesar García-Rodríguez; Luis Enrique Almaguer-Mederos; Tania Cruz-Mariño; José Miguel Laffita-Mesa Journal: Cerebellum Date: 2011-06 Impact factor: 3.847
Authors: Matthew A Picchietti; Daniel L Picchietti; Sandra J England; Arthur S Walters; Barbara V Couvadelli; Daniel S Lewin; Wayne Hening Journal: Sleep Date: 2009-04 Impact factor: 5.849
Authors: Stefan Seidel; Heinrich Garn; Markus Gall; Bernhard Kohn; Christoph Wiesmeyr; Markus Waser; Carmina Coronel; Andrijana Stefanic; Marion Böck; Markus Wimmer; Magdalena Mandl; Birgit Högl; Gerhard Klösch Journal: J Sleep Res Date: 2020-02-04 Impact factor: 3.981